Skip to main content
SpringerLink
Log in

Omalizumab add-on therapy cost effective in severe asthma in Spain

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was supported by a grant from Novartis Farmaceutica S.A.

Reference

  • Entrenas Costa LM, et al. Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study. PharmacoEconomics-Open : 25 Jan 2019. Available from: URL: https://doi.org/10.1007/s41669-019-0117-4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Omalizumab add-on therapy cost effective in severe asthma in Spain. PharmacoEcon Outcomes News 821, 21 (2019). https://doi.org/10.1007/s40274-019-5638-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5638-7

Search

Navigation